[Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 医药生物 G 测序仪龙头押注技术跃迁 [Table_ReportDate] 2026 年 03 月 02 日 [Table_ReportType] 医药生物行业周报（2 月第 4 周） [Table_S 行业观点： ummary] 请务必阅读文后重要声明及免责条款 [Table_Industry] [Table_BaseData] | 一、 市场周度回顾 3 | | | | --- | --- | --- | | 二、 行业要闻及重点公司公告 4 | | | | 2.1 | 行业重要事件 | 4 | | 2.2 | 行业要闻 | 4 | | 2.3 | 公司公告 | 5 | 1) 区间回顾。2 月 9 日-2 月 27 日，医药生物板块跌 0.32%，跑输 Wind 全 A（3.89%）和沪深 300（1.44 ...

Core Viewpoint - Shenzhen BGI Intelligent Manufacturing Technology Co., Ltd. plans to acquire 100% equity of Shenzhen BGI Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xifeng Technology Co., Ltd. for a total price of 365.7 million yuan, aiming to enhance its capabilities in spatial omics and nanopore sequencing technologies [2][5][12]. Transaction Overview - The acquisition involves cash payment for the equity of the two companies, with the total transaction price set at 365.7 million yuan, comprising 158 million yuan for Sanjian Qifa and 207.7 million yuan for Xifeng [2][5]. - Following the acquisition, BGI Intelligent Manufacturing will inject 70 million yuan into Sanjian Qifa and 60 million yuan into Xifeng to support their operations and business expansion [3][6]. Technology and Intellectual Property - Sanjian Qifa will acquire intellectual property rights related to spatial omics technology, with a transaction price of 65.34 million yuan [4][12]. - Xifeng will acquire intellectual property rights related to nanopore sequencing technology, with a transaction price of 56.17 million yuan [4][12]. Performance Commitment - BGI Technology, the counterparty, has made performance commitments regarding the profitability of the acquired companies. If the companies fail to meet the promised net profit during the commitment period, BGI Technology will provide cash compensation [4][12]. Financial Impact - The transaction is expected to have a short-term impact on the company's operating profits due to the acquired companies being in the R&D phase and not yet profitable. However, the long-term potential for innovation and commercialization is significant [8][12]. - The acquisition will not adversely affect the company's cash flow, as it has sufficient cash reserves and a strong cash-generating ability [8][12]. Strategic Importance - This acquisition is a strategic move to integrate cutting-edge technologies in spatial omics and nanopore sequencing, enhancing the company's competitive edge in the gene sequencing market [8][19]. - The combined capabilities will allow the company to offer comprehensive solutions from library construction to sequencing and data analysis, significantly improving service capabilities [18][21]. Market Positioning - BGI Intelligent Manufacturing aims to secure a leading position in the global sequencing market by integrating both short-read and long-read sequencing technologies, thus enhancing its strategic initiative and market competitiveness [19][20]. Approval Process - The transaction has been approved by the company's board of directors and will require further approval from the shareholders' meeting, with related parties abstaining from voting [7][23].

Core Insights - The life sciences instrument sector is experiencing significant capital inflow and technological innovation in 2025, with a notable trend towards domestic substitution [1][2] - The financing activity in the first half of 2025 has surpassed that of the same period in 2024, with a total of approximately 1.5 billion yuan raised across 13 financing events [2] Financing Overview - In the first half of 2025, 13 financing events were completed, totaling around 1.5 billion yuan, with a balanced distribution across various financing rounds: 4 in A round, 4 in B round, 3 in C round, and 2 in angel round [2] - Key financing events include: - Kunpeng Gene: over 100 million yuan in B round [2] - Yinsais: several hundred million yuan in C round [2] - Zhenmai Bio: 280 million yuan in C+ round, the highest amount in the first half [3][2] Sector Analysis - Sequencing and synthetic biology are leading the investment landscape, with sequencing-related companies accounting for over 30% of the financing events [3] - The market for sequencing instruments is expected to maintain a compound annual growth rate of over 20% due to increasing demand for precision medicine and single-cell sequencing [3] Synthetic Biology Financing - Synthetic biology has emerged as a hot investment area since 2024, continuing into 2025, with significant financing amounts [4] - Companies like Yinsais and Lingzhi Technology are focusing on nucleic acid synthesis and DNA synthesis, respectively, aligning with global trends in mRNA technology [4] AI and Advanced Instrumentation - Companies are integrating AI with high-end instrumentation, exemplified by Tianlu Technology's intelligent experimental design tools and Chaowei Jing's multi-photon microscope [5] - This trend indicates a shift towards interdisciplinary innovation, enhancing the competitiveness of domestic instruments [5] Domestic Instrumentation Landscape - Lid Health's substantial angel round financing has drawn attention, positioning the company as a comprehensive supplier of high-end life science instruments [6] - The company aims to consolidate the market by acquiring smaller players, drawing parallels with international leaders like Thermo Fisher [6] Policy and Market Dynamics - The rapid development of domestic life science instruments is driven by supportive policies and growing market demand, particularly in biomedicine and CGT sectors [7] - Despite active financing, domestic manufacturers face challenges such as reliance on imported core components and the need for brand recognition [7] Future Outlook - The life sciences instrument sector is expected to see a shift from broad investment strategies to a more focused approach, favoring companies with high technological barriers and significant domestic substitution potential [8] - The industry is anticipated to produce several "hidden champions" in niche areas within the next 3-5 years, moving towards the high end of the global value chain [8]